Literature DB >> 33620510

Organ donation after controlled cardiocirculatory death: confidence by clarity.

Thomas Bein1, Alain Combes2, Geert Meyfroidt3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33620510      PMCID: PMC7952349          DOI: 10.1007/s00134-021-06362-w

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Even if an impressive number of 6.337 organs from 1837 donors were transplanted in the Eurotransplant region in 2020 (a reduction of 667 donors compared to 2019), at the end of the year, the active waiting list remains high, with 14,020 patients (of whom 3502 on the waiting list for heart, lung, or liver transplantation) still in need of an organ upon which their lives depend [1]. Historically, organ donation from deceased donors was possible when they had explicitly expressed the will to donate and were determined to be brain dead, defined as the complete and irreversible loss of all brain functions, but this concept may reveal structural deficiency (recognition and reporting of potential donors, realization of donations) [2]. Ethical evolutions and new scientific insights have changed policies since these early years of cadaver organ donations. First, some countries, such as Austria, Belgium, the Netherlands, and Spain, now have presumed consent or opt-out (instead of opt-in) donor legislations, and Ireland is expected to implement such a legislation soon. These countries typically have high donor rates. In ethical considerations of opt-in or opt-out regulations, important reflections on the weighting of the principles of autonomy, benevolence, solidarity and liberty of the individual are inherent. But whatever the system chosen, trust must be generated by adequate and fair communication [3]. Second, in patients who do not meet formal brain death criteria, donation after cardiac or cardiocirculatory death (DCCD), previously known as ‘non-heart-beating’ donation, is an alternative option. This can be performed following unsuccessful resuscitation in an uncontrolled DCCD protocol but is more frequently done in the context of controlled DCCD (cDCCD) following withdrawal of life-sustaining therapies (WLST) [4]. The procedure for cDCCD is as follows: after cessation of systemic circulation, and a short standoff time (various definitions due to different national laws) to exclude autoresuscitation, the patient is declared dead according to cardiovascular criteria and can become an organ donor. The dead donor rule is strictly respected. Nowadays, several techniques for organ preservation, either in situ, ex situ, or with machine perfusion, exist and allow for good quality of transplantable organs, and overall good results in the transplanted recipient [5]. During such procedures of post mortem organ recovery a strict focus must be given by monitoring to exclude brain reperfusion [6]. Some countries still do not allow cDCCD due to legal and ethical concerns [7]. To address these concerns, carefully addressed guidelines, written with scientific, legal, and ethical expertise, are necessary, and should cover the timing of determination of death, the issue of proper consent, the role of surrogate decision makers, the preservation of dignity of the dying patient, as well as organ preservation measures [8]. In the current issue of Intensive Care Medicine, Domínguez-Gil et al. have published a Collaborative Statement of an international expert group regarding the management of cDCCD [9]. Their statement aims to clarify some of the clinical, ethical, legal, and practical aspects of this procedure, and will hopefully contribute to a broader acceptance. The importance of such precise statements, born in a process involving multiple iterations, cannot be underestimated in the current situation of donor organ shortage and the many different legislations and practices across Europe. The statement focuses thoroughly on the specific challenges of determining a prognosis that justifies WLST, as well as on specific aspects of the determination of death in this scenario, and measures of perfusion maintenance to optimize the function of transplantable organs. The manuscript and statements will appeal not only to those colleagues involved in the care of transplant patients, but to the entire intensive care community [10]. In a clear and concise way, these statements promote transparency and offer practical guidance for the cDCCD procedure, in the context of controlled withdrawal of therapeutic support, which should be part of daily practice in intensive care regardless of donation perspectives. However, even if such broad consensus guidelines [9] are an important and necessary step to address the controversies surrounding the DCD procedure, their publication and broad dissemination will not automatically solve all problems in the context of cDCCD. It is clear that the transition from a dying patient who has experienced a cardiac arrest and is undergoing resuscitative efforts for organ preservation touches essential questions on life and death, and mistrust might be fostered without a clear, public discussion and matched transparency (Fig. 1). James F. Childress, co-author of the landmark book Principles of Biomedical Ethics and a leading figure in the field of contemporary bioethics, acknowledges that some health care professionals and institutions continue to suffer from ongoing conflicts of obligation, loyalty, and interests in the context of donation after circulatory death [11]. As argued by Jessie Cooper [12], not all these concerns can be reduced to abstract directives for practice or should be dealt with as an organisational problem. Even if the overall benefit of organ donation after circulatory death is clear, this may not automatically diminish the challenges of a specific care for dying patients—quasi in a utilitarian manner [13]. Furthermore, Childress raises an additional point which may not be sufficiently addressed by statements: “Trust in the healthcare system is the prime consideration” [11]. Such trust can only be established by an open and transparent public debate, where medical and ethical domain experts have a crucial role. In addition, all stakeholders, including patients, and political decision makers should be involved as well. Due to nation’s histories as well as cultural/religious beliefs and values and existing frameworks in some countries, like Germany ‘Non-heart-beating donors are ineligible’ [14] at the moment. Maybe health politics, other stakeholders and the affected people can find inspiration here and should look at those countries where cDCCD is a widely accepted practice. An ethically careful and responsible practice of cDCCD will only be guaranteed when this measure is ‘deeply embedded with specific organisational settings’ [12]. In this way, the statements and algorithm by Domínguez-Gil et al. [9] are important further steps to promote cDCCD as a normal end-of-life practice for eligible potential donors. Moreover, and even broader, they are an important contribution towards the general societal acceptance of this end-of-life challenging procedure.
Fig. 1

Factors influencing trust and acceptance in the context of controlled organ donation after the circulatory determination of death

Factors influencing trust and acceptance in the context of controlled organ donation after the circulatory determination of death
  13 in total

Review 1.  Opt-in or opt-out for organ transplantation.

Authors:  Sadek Beloucif
Journal:  Curr Opin Anaesthesiol       Date:  2012-04       Impact factor: 2.706

2.  Organ donation after circulatory determination of death: lessons and unresolved controversies.

Authors:  James F Childress
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

3.  Organs and organisations: Situating ethics in organ donation after circulatory death in the UK.

Authors:  Jessie Cooper
Journal:  Soc Sci Med       Date:  2018-05-25       Impact factor: 4.634

4.  Ex vivo perfusion techniques: state of the art and potential applications.

Authors:  Marcelo Cypel; Arne Neyrinck; Tiago N Machuca
Journal:  Intensive Care Med       Date:  2019-02-25       Impact factor: 17.440

5.  Expanding the pool of deceased organ donors: the ICU and beyond.

Authors:  Alexander Manara; Francesco Procaccio; Beatriz Domínguez-Gil
Journal:  Intensive Care Med       Date:  2019-02-06       Impact factor: 17.440

Review 6.  Organ donation after circulatory death: current status and future potential.

Authors:  Martin Smith; B Dominguez-Gil; D M Greer; A R Manara; M J Souter
Journal:  Intensive Care Med       Date:  2019-02-06       Impact factor: 17.440

7.  The incidence of potential missed organ donors in intensive care units and emergency rooms: a retrospective cohort.

Authors:  Demetrios J Kutsogiannis; Sonal Asthana; Derek R Townsend; Gurmeet Singh; Constantine J Karvellas
Journal:  Intensive Care Med       Date:  2013-05-24       Impact factor: 17.440

8.  [Non-heart-beating donors are ineligible].

Authors:  W Heide
Journal:  Nervenarzt       Date:  2016-02       Impact factor: 1.214

9.  Maintaining the permanence principle for death during in situ normothermic regional perfusion for donation after circulatory death organ recovery: A United Kingdom and Canadian proposal.

Authors:  Alex Manara; Sam D Shemie; Stephen Large; Andrew Healey; Andrew Baker; Mitesh Badiwala; Marius Berman; Andrew J Butler; Prosanto Chaudhury; John Dark; John Forsythe; Darren H Freed; Dale Gardiner; Dan Harvey; Laura Hornby; Janet MacLean; Simon Messer; Gabriel C Oniscu; Christy Simpson; Jeanne Teitelbaum; Sylvia Torrance; Lindsay C Wilson; Christopher J E Watson
Journal:  Am J Transplant       Date:  2020-01-27       Impact factor: 8.086

10.  Expanding controlled donation after the circulatory determination of death: statement from an international collaborative.

Authors:  Beatriz Domínguez-Gil; Nancy Ascher; Alexander M Capron; Dale Gardiner; Alexander R Manara; James L Bernat; Eduardo Miñambres; Jeffrey M Singh; Robert J Porte; James F Markmann; Kumud Dhital; Didier Ledoux; Constantino Fondevila; Sarah Hosgood; Dirk Van Raemdonck; Shaf Keshavjee; James Dubois; Andrew McGee; Galen V Henderson; Alexandra K Glazier; Stefan G Tullius; Sam D Shemie; Francis L Delmonico
Journal:  Intensive Care Med       Date:  2021-02-26       Impact factor: 17.440

View more
  1 in total

1.  EISOR Delivery: Regional experience with sharing equipe, equipment & expertise to increase cDCD donor pool in time of pandemic.

Authors:  Alessandro Circelli; Marta Velia Antonini; Emiliano Gamberini; Andrea Nanni; Marco Benni; Carlo Alberto Castioni; Giovanni Gordini; Stefano Maitan; Federico Piccioni; Giuseppe Tarantino; Manila Prugnoli; Martina Spiga; Mattia Altini; Fabrizio Di Benedetto; Matteo Cescon; Piergiorgio Solli; Fausto Catena; Giorgio Ercolani; Emanuele Russo; Vanni Agnoletti
Journal:  Perfusion       Date:  2022-05-28       Impact factor: 1.581

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.